Differences on immune biomarkers between KRAS G12C and KRAS non-G12C mutated non-small cell lung cancer

被引：0
|
作者：
Pinto, L. Masfarre [1 ]
Parreira, A. S. D. F. M. [2 ]
Unanua, N. Castro [3 ]
Rocha, P. [4 ]
Ruiz, I. Morilla [5 ]
Sanchez, L. Teijeira [5 ]
Clave, S. [6 ]
Gorro, N. Navarro [7 ]
Mora, R. Bach [8 ]
Sanchez, I. [6 ]
Campos, M. A. Galindo [9 ]
Garcia, A. Taus [10 ]
Martinez, A. Azkarate [11 ]
Fabregat, R. Marse [12 ]
Paricio, B. Bellosillo [13 ]
Arasanz, H. [14 ]
Aguillo, M. Martinez [5 ]
Arriola, E. [7 ]
机构：
[1] Hosp Mar Parc Salut Mar, Dept Oncol, Barcelona, Spain
[2] Hosp Univ son Espases, Med Oncol, Palma de Mallorca, Spain
[3] Hosp Univ Navarra, Oncobiona Med Oncol Dept, Pamplona, Spain
[4] IMIM Inst Hosp Mar dInvest Med, Canc Res Program, Barcelona, Spain
[5] Complejo Hosp Navarra, Dept Oncol, Royal Navarre Hosp, Pamplona, Spain
[6] Hosp Mar Parc Salut Mar, Dept Pathol, Barcelona, Spain
[7] Hosp Mar Parc Salut Mar, Dept Med Oncol, Barcelona, Spain
[8] Parc Salut Mar, Dept Oncol, Barcelona, Spain
[9] IMIM Inst Hosp Mar dInvest Med, Doctor Aiguader 88, Barcelona, Spain
[10] Hosp Mar Parc Salut Mar, Med Oncol, Barcelona, Spain
[11] Hosp Univ Son Espases, Dept Med Oncol, Palma de Mallorca, Spain
[12] Hosp Univ Son Espases, Dept Oncol, Palma de Mallorca, Spain
[13] Hosp Mar Parc Salut Mar, Mol Biol Dept, Barcelona, Spain
[14] Complejo Hosp Navarra, Dept Med Oncol, Royal Navarre Hosp, Pamplona, Spain
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2440
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1408P
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients
    Si-Yang Liu
    Hao Sun
    Jia-Ying Zhou
    Guang-Ling Jie
    Zhi Xie
    Yang Shao
    Xian Zhang
    Jun-Yi Ye
    Chun-Xiang Chen
    Xu-Chao Zhang
    Qing Zhou
    Jin-Ji Yang
    Yi-Long Wu
    Biomarker Research, 8
  • [32] Safety and Efficacy of D-1553 in Patients with KRAS G12C Mutated Non-Small Cell Lung Cancer: A Phase 1 Trial
    Lu, S.
    Jian, H.
    Zhang, Y.
    Song, Z.
    Zhao, Y.
    Wang, P.
    Jiang, L.
    Gong, Y.
    Zhou, J.
    Dong, X.
    Yang, N.
    Fang, J.
    Zhuang, W.
    Cang, S.
    Ma, R.
    Shi, J.
    Wu, P.
    Lu, J.
    Xiang, Z.
    Shi, Z.
    Zhang, L.
    Wang, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S11 - S11
  • [33] Targeting WEE1 to improve the therapy of KRAS G12C mutant non-small cell lung cancer
    Yamamoto, Gaku
    Tanaka, Kosuke
    Kamata, Ryo
    Mori, Shunta
    Liu, Jie
    Yamauchi, Toyohiro
    Sakae, Yuta
    Ohashi, Akihiro
    Kobayashi, Susumu S.
    CANCER RESEARCH, 2023, 83 (07)
  • [34] KRAS G12C-mutant driven non-small cell lung cancer (NSCLC)
    Rosell, Rafael
    Codony-Servat, Jordi
    Gonzalez, Jessica
    Santarpia, Mariacarmela
    Jain, Anisha
    Shivamallu, Chandan
    Wang, Yu
    Gimenez-Capitan, Ana
    Molina-Vila, Miguel A.
    Nilsson, Jonas
    Gonzalez-Cao, Maria
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2024, 195
  • [35] The histopathological spectrum and molecular changes associated with KRAS G12C mutation in non-small cell lung carcinoma
    Li, Jing Jing
    Wu, Xiao Juan
    Farzin, Mahtab
    Bray, Victoria
    Williamson, Jonathan
    Pal, Abhiji
    Yip, Po Yee
    Hagelamin, Abeer
    Ding, Pei
    Nindra, Udit
    Vinod, Shalini
    French, Bruce
    Chua, Wei
    Gupta, Ruta
    Cooper, Wendy A.
    Wang, Bin
    Lee, C. Soon
    PATHOLOGY, 2024, 56 (06) : 786 - 794
  • [36] Selinexor (XPO1 inhibitor) in combination with tepotinib (MET inhibitor) potentially inhibits SHOC2 and KRAS G12C in KRAS G12C mutant non-small cell lung cancer
    Rosell, R.
    Jain, A.
    Codony-Servat, J.
    Shivamallu, C.
    Kollur, S. P.
    Prasad, A.
    Vishwanath, P.
    Jantus Lewintre, E.
    Ito, M.
    Cardona Zorrilla, A. F.
    Arrieta Rodriguez, O. G.
    Pedraz-Valdunciel, C.
    Gonzalez Nieto, J.
    Aguilar, A.
    Molina-Vila, M. A.
    Gonzalez Cao, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S1188 - S1188
  • [37] Durability of Clinical Benefit and Biomarkers in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Sotorasib, a KRAS(G12C) Inhibitor
    Hong, D. S.
    Bang, Y. -J.
    Barlesi, F.
    Durm, G.
    Falchook, G.
    Govindan, R.
    Dy, G.
    Park, K.
    Strickler, J.
    Burns, T.
    Kim, J.
    Ang, A.
    Lipford, J. R.
    Ngarmchamnanrith, G.
    Anderson, A.
    Li, B. T.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S28 - S29
  • [38] Chromatin modification driving sub-clonal resistance to KRAS G12C combination therapies in KRAS mutant non-small cell lung cancer
    Li, Chendi
    Qin, Qian
    Syed, Mohammed Usman
    Nimbalkar, Anahita
    Karakyriakou, Barbara
    Clark, Sarah E.
    Saiki, Anne Y.
    Hughes, Paul E.
    Ott, Chris
    Pinello, Luca
    Hata, Aaron N.
    CANCER RESEARCH, 2023, 83 (07)
  • [39] How to manage KRAS G12C-mutated advanced non-small-cell lung cancer
    Ricciuti, Biagio
    Mira, Alessia
    Andrini, Elisa
    Scaparone, Pietro
    Michelina, Sandra Vietti
    Pecci, Federica
    Cantini, Luca
    De Giglio, Andrea
    Lamberti, Giuseppe
    Ambrogio, Chiara
    Metro, Giulio
    DRUGS IN CONTEXT, 2022, 11
  • [40] KRAS G12C mutated lung adenocarcinomas: a morphological and molecular cartography
    Pirlog, R.
    Piton, N.
    Marguet, F.
    Lamy, A.
    Sabourin, J.
    VIRCHOWS ARCHIV, 2021, 479 : S162 - S162
12345